Celgene And Acceleron Announce Luspatercept Achieved Primary And All Key Secondary Endpoints In Phase III 'BELIEVE' Study In Adults With Transfusion-Dependent Beta-Thalassemia; Regulatory Submissions Planned In US And Europe In 1H 2019